J&J to stop studies of depression drug due to low effectiveness
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
BioSpace1d
J&J Axes Late-Stage Depression Trial After Underwhelming Efficacy
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
The Manila Times5d
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, ...
Psychedelic: MindMed reports Q4 earnings results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...
pharmaphorum4d
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato ... hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies ...
Medical Marketing & Media2d
Rx Rundown: AbbVie, Jazz Pharmaceuticals, Sofinnova Partners and more
AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...
pharmaphorum2d
Axsome bounces back as FDA clears depression drug
That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks.
Frontiers5d
Psychodynamic profiles of major depressive disorder and generalized anxiety disorder in China
The current study aims to adopt the OPD system to investigate the psychodynamic profiles of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in China, targeting patients with ...